Plander M, Brockhoff G, Barlage S, Schwarz S, Rothe G, Knuechel R
Department of Hematology, University Teaching Hospital of Vas County, Szombathely, Hungary.
Cytometry A. 2003 Jul;54(1):66-74. doi: 10.1002/cyto.a.10051.
Simultaneous analysis of DNA and immunophenotype of lymphoma cells by flow cytometry allows the calculation of the proliferative activity and aneuploidy in even a small lymphoma population. Unfavorable DNA binding characteristics or spectral features of DNA dyes impair the accuracy of multiparameter DNA analysis and limit their clinical application. We describe here a reliable and reproducible application of both three- and four-color multiparameter DNA analysis.
After immunostaining of fresh samples of peripheral blood, bone marrow and single cell suspensions of lymph nodes from healthy and lymphoma patients, a methanol fixation for TO-PRO-3 and DRAQ5 staining was tested.
The red-excitable TO-PRO-3 on a FACSCalibur is limited to two-color antigen staining including fluorescein-isothiocyanate and phycoerythrin-labeled monoclonal antibodies due to its broad excitation spectrum. Although DRAQ5 is only applicable to flow cytometers equipped with a single argon laser emitting 488-nm light, its emission spectrum can be easily separated from the FITC, PE, and PE/Texas-Red emissions. DRAQ5 showed almost identical stoichiometric DNA binding characteristics as propidium iodide. Coefficient of variation produced by DRAQ5 staining is in the range of 3.5 and is adequate for detecting aneuploid amd near-diploid cells.
These advantageous features of DRAQ5 make it a reliable candidate for multiparameter clinical studies.
通过流式细胞术同时分析淋巴瘤细胞的DNA和免疫表型,即使是少量淋巴瘤细胞群体也能计算其增殖活性和非整倍体情况。DNA染料不利的DNA结合特性或光谱特征会损害多参数DNA分析的准确性并限制其临床应用。我们在此描述了三色和四色多参数DNA分析的可靠且可重复的应用。
对健康人和淋巴瘤患者的外周血、骨髓新鲜样本以及淋巴结单细胞悬液进行免疫染色后,测试了用于TO-PRO-3和DRAQ5染色的甲醇固定方法。
由于其宽激发光谱,FACSCalibur上的红色激发TO-PRO-3仅限于双色抗原染色,包括异硫氰酸荧光素和藻红蛋白标记的单克隆抗体。尽管DRAQ5仅适用于配备发射488nm光的单氩激光的流式细胞仪,但其发射光谱可轻松与FITC、PE和PE/德克萨斯红发射光谱分离。DRAQ5显示出与碘化丙啶几乎相同的化学计量DNA结合特性。DRAQ5染色产生的变异系数在3.5范围内,足以检测非整倍体和近二倍体细胞。
DRAQ5的这些优势使其成为多参数临床研究的可靠候选者。